Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Prednisolone
Drug ID BADD_D01831
Description Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status approved; vet_approved
ATC Code A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB00860
KEGG ID D00472
MeSH ID D011239
PubChem ID 5755
TTD Drug ID D0D1SG
NDC Product Code 38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII 9PHQ9Y1OLM
Synonyms Prednisolone | Predate | Predonine | Di-Adreson-F | Di Adreson F | DiAdresonF
Chemical Information
Molecular Formula C21H28O5
CAS Registry Number 50-24-8
SMILES CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary oedema22.01.03.003; 02.05.02.0030.000192%
Pulmonary thrombosis24.01.06.002; 22.06.02.0030.000087%Not Available
Pupillary reflex impaired17.02.11.007; 06.05.03.0090.000035%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.000140%
Purpura fulminans24.07.06.013; 23.06.01.010; 01.01.02.0090.000035%Not Available
Pustular psoriasis10.02.01.102; 23.03.14.0060.000199%Not Available
Pyoderma gangrenosum23.07.03.001; 16.32.03.005; 10.04.02.0090.000070%Not Available
Pyrexia08.05.02.0030.003331%
Rales22.12.01.0110.000052%Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.0290.000199%Not Available
Rash maculo-papular23.03.13.0040.000227%
Rash papular23.03.13.0170.000070%Not Available
Rebound effect08.06.02.0090.000419%Not Available
Rectal cancer16.13.01.003; 07.21.05.0020.000052%Not Available
Rectal ulcer07.04.01.0020.000035%
Renal haemorrhage24.07.07.002; 20.01.02.013; 12.01.05.0040.000035%
Renal infarct20.01.07.008; 24.01.11.0040.000070%Not Available
Renal pain20.02.03.0030.000035%Not Available
Renal vein thrombosis20.01.07.011; 24.01.11.0020.000035%Not Available
Respiratory acidosis22.02.02.004; 14.01.04.0020.000087%Not Available
Respiratory alkalosis22.02.02.005; 14.01.05.0010.000087%Not Available
Respiratory disorder22.02.07.0020.000105%Not Available
Respiratory distress22.02.01.0120.000192%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.001311%
Restlessness19.11.02.002; 17.02.05.0210.000252%
Retinal degeneration06.09.03.0020.000035%Not Available
Retinal deposits06.09.03.0050.000035%Not Available
Retinal detachment12.01.04.004; 06.09.03.0030.000444%
Retinal disorder06.08.03.0050.000192%Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene